Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderlymultiple myeloma.
Paiva B et al. Blood. 2016 Apr 26. pii: blood-2016-03-705319. [Epub ahead of print].
Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab.
Postelnek J et al. AAPS J. 2016 Apr 26. [Epub ahead of print].
Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease – a Pilot Study.
Windrichova J et al. Anticancer Res. 2016 Apr;36(4):1973-8.
11C-Acetate PET/CT Monitoring Therapy of Multiple Myeloma.
Zhu W et al. Clin Nucl Med. 2016 Apr 6. [Epub ahead of print].
Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring ofmyeloma bone disease.
Fu R et al. Ann Hematol. 2016 Apr 27. [Epub ahead of print].
Absolute lymphocyte count as a prognostic marker in newly diagnosed multiple myeloma patients.
Suriu C et al. Int J Lab Hematol. 2016 Mar 28. doi: 10.1111/ijlh.12482. [Epub ahead of print].